Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)

Bruce Strober,Hervé Bachelez,Jeffrey Crowley,Boni E. Elewski,Melinda Gooderham,Alan Menter,Robert Strohal,Michael M. Chen,Tianshuang Wu,Tianyu Zhan,Huzefa Photowala,April Armstrong

DOI: https://doi.org/10.1111/jdv.19748

2024-01-07

Journal of the European Academy of Dermatology and Venereology

Abstract:Background Psoriasis is an inflammatory skin disease that impacts a heterogeneous group of patients and can have multiple clinical manifestations. Risankizumab is approved for the treatment of moderate‐to‐severe plaque psoriasis. Objectives To evaluate the long‐term efficacy of risankizumab according to baseline patient characteristics, and for the treatment of high‐impact disease manifestations (nail, scalp and palmoplantar psoriasis), through 256 weeks of continuous treatment in the phase 3 LIMMitless study. Methods This subgroup analysis evaluated pooled data from patients with moderate‐to‐severe plaque psoriasis who were randomized to risankizumab 150 mg during two double‐blind, phase 3, 52‐week base studies (UltIMMa‐1/2; NCT02684370/NCT02684357) and were enrolled in the phase 3 LIMMitless open‐label extension study (NCT03047395). Subgroup assessments included the proportion of patients who achieved ≥90%/100% improvement in Psoriasis Area and Severity Index (PASI 90/100). Among patients with nail, scalp and/or palmoplantar psoriasis in addition to skin psoriasis, assessments included changes from baseline in and resolution of these three psoriatic manifestations. Results Overall, a numerically similar proportion of patients (N = 525) achieved PASI 90/100 through Week 256, regardless of their baseline age, sex, body mass index, weight, PASI or psoriatic arthritis status. Patients with nail, scalp and/or palmoplantar psoriasis experienced substantial improvements in manifestation‐specific indices (mean improvement from baseline to Week 256 of >81%, >94% and >97%, respectively); in patients with all three manifestations (N = 121), 44.6% achieved complete clearance of these manifestations at Week 256. Conclusions Risankizumab demonstrated generally consistent efficacy through 256 weeks across patient subgroups and showed durable long‐term efficacy for psoriatic disease manifestations.

dermatology